(Total Views: 369)
Posted On: 03/24/2018 1:57:31 PM
Post# of 72447
Most small biotechs pin their company's future on one drug. If they are lucky, they get ONE drug into clinical trials.
We have THREE drugs, one of which (Brilacidin) has been proven in clinical trials to be effective against 3 very different conditions. It is unbelievable that a savvy investor can invest in treatments for at least 5 different diseases, at this incredibly low price.
MARKET CAPS:
IPIX.......75 million -- 3 drugs, clinical trials for 5 different applications
NNVC....55+ million -- no clinical trials whatsoever
AXON....154+ million -- one failed clinical trial for a drug that had failed before
CTSO... 224- million -- has CE mark in Europe for a blood filter device. No U.S. clinical trial
CTSO should give you an idea of where IPIX's stock price should be for ONE successful clinical trial at this stage. Now, multiply be at least 3, or maybe 5.
We have THREE drugs, one of which (Brilacidin) has been proven in clinical trials to be effective against 3 very different conditions. It is unbelievable that a savvy investor can invest in treatments for at least 5 different diseases, at this incredibly low price.
MARKET CAPS:
IPIX.......75 million -- 3 drugs, clinical trials for 5 different applications
NNVC....55+ million -- no clinical trials whatsoever
AXON....154+ million -- one failed clinical trial for a drug that had failed before
CTSO... 224- million -- has CE mark in Europe for a blood filter device. No U.S. clinical trial
CTSO should give you an idea of where IPIX's stock price should be for ONE successful clinical trial at this stage. Now, multiply be at least 3, or maybe 5.
(3)
(0)
